Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Penn Pharma and Xcelience have signed a joint venture agreement to provide Capsugel’s Xcelodose precision powder micro-dosing system technology on a global basis.
Subscribe to our email newsletter
Xcelodose is a registered trademark of Capsugel, a division of Pfizer.
Penn Pharma and Xcelience claimed that the joint venture provides pharmaceutical and biotechnology companies the opportunity to manufacture first in human batches closer to the clinical sites.
Derek Hennecke, president and CEO of Xcelience, said: “This joint venture will create a powerful partnership between two providers who share a common commitment to quality, innovation, and building client relationships based on trust and performance.”
Paul Wituschek, global sales and marketing director of Penn Pharma, said: “Xcelience has more than six years experience in powder in capsule technology and has processed more than 100 clinical supply batches using the Xcelodose technology.
“Penn will be able to immediately leverage this expertise to provide this important accelerated development option to our clients.”